
Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Description
Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Next Generation Sequencing (NGS) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Next Generation Sequencing (NGS) Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Next Generation Sequencing (NGS) Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Next Generation Sequencing (NGS) Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
297 Pages
- About GlobalData
- Next Generation Sequencing (NGS) Tests Overview
- Next Generation Sequencing (NGS) Tests - Pipeline Products by Stage of Development
- Next Generation Sequencing (NGS) Tests - Pipeline Products by Territory
- Next Generation Sequencing (NGS) Tests - Pipeline Products by Regulatory Path
- Next Generation Sequencing (NGS) Tests - Pipeline Products by Estimated Approval Date
- Next Generation Sequencing (NGS) Tests - Ongoing Clinical Trials
- Next Generation Sequencing (NGS) Tests Companies - Pipeline Products by Stage of Development
- Next Generation Sequencing (NGS) Tests - Companies Pipeline Products by Stage of Development
- 4bases SA Company Overview
- AccuraGen Inc Company Overview
- ACT Genomics Co LTD Company Overview
- Adaptive Biotechnologies Corp Company Overview
- Almac Diagnostic Services Ltd Company Overview
- Amoy Diagnostics Co Ltd Company Overview
- AnchorDx Medical Co Ltd Company Overview
- ArcherDx Inc Company Overview
- Berry Oncology Corp Company Overview
- BGI Genomics Co Ltd Company Overview
- Biocartis Group NV Company Overview
- Biodesix Inc Company Overview
- BioLink Company Overview
- bioTheranostics Inc Company Overview
- Boston University Company Overview
- Buhlmann Laboratories AG Company Overview
- Burning Rock Biotech Ltd Company Overview
- Cardiff Oncology Inc Company Overview
- CCM Biosciences Inc Company Overview
- Cerba HealthCare SAS Company Overview
- Cyclomics BV Company Overview
- DCGen Co Ltd Company Overview
- Eiken Chemical Co Ltd Company Overview
- Epic Sciences Inc Company Overview
- Epigenomics AG Company Overview
- FBB Biomed Inc Company Overview
- Feng Biosciences Inc Company Overview
- First Genetics JCS Company Overview
- Flomics Biotech Company Overview
- Foundation Medicine Inc Company Overview
- Gencurix Inc Company Overview
- GeneCast Biotechnology Co Ltd Company Overview
- Geneseeq Technology Inc Company Overview
- Genetron Health (Beijing) Co Ltd Company Overview
- Genomic Health Inc Company Overview
- GigaGen Inc Company Overview
- HaploX Biotechnology Co Ltd Company Overview
- Haystack Oncology Inc Company Overview
- HTG Molecular Diagnostics Inc Company Overview
- Illumina Inc Company Overview
- Immunovia AB Company Overview
- Inivata Ltd Company Overview
- Insight Genetics Inc Company Overview
- Invivoscribe Inc Company Overview
- IvyGene Diagnostics Company Overview
- Laboratory Corp of America Holdings Company Overview
- Leto Laboratories Co Ltd Company Overview
- Lucence Diagnostics Pte Ltd Company Overview
- MedySapiens Inc Company Overview
- Mega Genomics Ltd Company Overview
- Micronoma Company Overview
- MolecularMD Corp Company Overview
- NGeneBio Co Ltd Company Overview
- Novigenix SA Company Overview
- Novomics Co Ltd Company Overview
- NuGEN Technologies Inc Company Overview
- NuProbe Inc Company Overview
- Oncodiag Company Overview
- OncoDNA SA Company Overview
- OncoSpire Genomics Company Overview
- OrigiMed Inc Company Overview
- Otsuka Medical Devices Co Ltd Company Overview
- Pasteur Institute Company Overview
- Personal Genome Diagnostics Inc Company Overview
- Pillar Biosciences Inc Company Overview
- Predicine Inc Company Overview
- Predictive Biosciences Inc (Inactive) Company Overview
- PT PathGen Diagnostik Teknologi Company Overview
- Qiagen NV Company Overview
- Quantgene Inc Company Overview
- Queen's University Company Overview
- RealSeq Biosciences Inc Company Overview
- Rhodx Inc Company Overview
- Roche Diagnostics International Ltd Company Overview
- SeqOne SAS Company Overview
- Silicon Biosystems S.p.A. Company Overview
- Sophia Genetics SA Company Overview
- Sostos LLC Company Overview
- Spectrum Solutions LLC Company Overview
- Sysmex Corp Company Overview
- Sysmex Inostics GmbH Company Overview
- Tempus Health Inc Company Overview
- Tempus Labs Inc Company Overview
- Thermo Fisher Scientific Inc Company Overview
- Trivitron Healthcare Pvt Ltd Company Overview
- TwinStrand Biosciences Inc Company Overview
- University of Chicago Company Overview
- University of Michigan Rogel Cancer Center Company Overview
- University of Texas Health Science Center at Houston Company Overview
- Veracyte Inc Company Overview
- Vyant Bio Inc (Inactive) Company Overview
- May 03, 2024: Decisiondx-Scc Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
- Apr 29, 2024: GenomOncology Introduces Expanded Support for Germline Testing in GO Pathology Workbench
- Apr 24, 2024: TwinStrand Biosciences Initiates Regulatory Approval Process for Duplex Sequencing Mutagenesis Assays with OECD
- Apr 23, 2024: Pillar Biosciences oncoReveal CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq Dx System
- Apr 11, 2024: German Gynecological Oncology Group (AGO) Recognizes BluePrint in Breast Cancer Guidelines
- Apr 11, 2024: Predicine Introduces Predicinecare NGS Kit for Tumor Profiling
- Apr 05, 2024: Predicine Introduces PredicineCARE NGS Kit for Global Clinical Trials, CDx Development and Patient Testing
- Apr 04, 2024: Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx- Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer
- Mar 26, 2024: 10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
- Mar 21, 2024: Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Mar 19, 2024: Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
- Mar 19, 2024: Singular Genomics Systems Reports Results for the Quarter Ended in December – Earnings
- Mar 08, 2024: Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
- Mar 08, 2024: Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint + BluePrint's Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
- Mar 07, 2024: In Novel Cohort, New Data Confirms DecisionDx-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
- Feb 27, 2024: Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
- Feb 21, 2024: Tempus Expanding Access to its Next-Generation Sequencing Tests as an In-Network Provider for Cigna
- Feb 06, 2024: Volta Labs and Integrated DNA Technologies Partner to Advance Target Enrichment Workflows
- Jan 18, 2024: New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences' DecisionDx-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
- Jan 18, 2024: Tempus launches MRD assay for colorectal cancer research
- Jan 18, 2024: Quantum-Si Introduces World's First Next-Generation Protein Sequencer in Japan with Addition of New Distributor
- Jan 17, 2024: Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling
- Jan 16, 2024: Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
- Jan 14, 2024: Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference – Hawaii
- Jan 09, 2024: Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
- Jan 09, 2024: Quest Diagnostics and Ultima Collaborate to Scale Ultima's Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
- Jan 08, 2024: Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD technology in phase II clinical trial for unresectable stage III NSCLC
- Jan 04, 2024: Geneseeq scores FDA breakthrough designation for cancer detection device
- Dec 27, 2023: Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics' RaDaR Test
- Dec 14, 2023: Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD in Clinical Study of Early-Stage Triple-Negative Breast Cancer
- Dec 09, 2023: Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ in Patients with Blood Cancers at the 65th ASH Annual Meeting
- Dec 05, 2023: Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of Clonoseq MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
- Dec 05, 2023: NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
- Dec 01, 2023: Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium
- Nov 28, 2023: NGeneBio's Blood Cancer Diagnostic Panel Gets Permit in Thailand
- Nov 20, 2023: U.S. FDA Approves FoundationOne CDx as a Companion Diagnostic for AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) to Identify Patients with HRPositive, HER2-Negative Advanced Breast Cancer
- Nov 20, 2023: Roswell Park Launches Advanced, High-Speed Blood Cancer Test
- Nov 15, 2023: Tempus Announces Medicare Coverage for Tempus|xT Across Solid Tumor and Hematologic Malignancies
- Nov 14, 2023: Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
- Nov 06, 2023: Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
- Nov 06, 2023: NGeneBio Releases Upgraded NGS-Based Companion Diagnostics for Cancer
- Oct 26, 2023: Foundation Medicine Announces Participation in National Cancer Institute's ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug Combinations
- Oct 21, 2023: Foundation Medicine Expands Partnership With Sequanta to Provide Both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings
- Oct 19, 2023: Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting
- Oct 18, 2023: New Data Highlights Clinical Utility and Performance of Castle Biosciences' Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference
- Oct 17, 2023: Predicine Announces Six Studies Showcasing Mrd and Liquid Biopsy Innovations at ESMO 2023
- Oct 15, 2023: Burning Rock Received Breakthrough Device Designation from China's NMPA for its Multi-Cancer Early Detection Test
- Oct 12, 2023: FDA Approves FoundationOneCDx and FoundationOnLiquid CDx as Companion Diagnostics for Pfizer's BRAFTOVI (encorafenib) in Combination With MEKTOVI (binimetinib) to Identify Patients with BRAF V600E Alterations in Metastatic NSCLC
- Oct 10, 2023: Karius Test Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood Cancer
- Oct 09, 2023: U.S. Food and Drug Administration (FDA) Approves FoundationOne CDx as a Companion Diagnostic for Lilly's Retevmo (selpercatinib) for Certain Patients with Solid Tumors
- Oct 03, 2023: Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of Decisiondx-Scc in Patients With Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy
- Sep 28, 2023: New Neoadjuvant Trial Confirms the Predictive Utility of Mammaprint + Blueprint
- Sep 20, 2023: Predicine Announces New Study Published in the New England Journal of Medicine Demonstrating Clinical Utility of Its Mrd Liquid Biopsy Assay in Supporting Genentech's Phase 1 Clinical Trial of Divarasib
- Sep 19, 2023: Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy Testing
- Sep 19, 2023: Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
- Sep 07, 2023: Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer
- Aug 22, 2023: New Study Shows UroAmp Can Detect Bladder Cancer Not Found by Cystoscopy or Urine Cytology
- Aug 22, 2023: Myriad Genetics And Onsite Women's Health Partner To Help More Women Understand Breast Cancer Risk
- Aug 22, 2023: Geneseeq Gains CE Marks For NGS-based Test Kits For Solid Tumors And Hematological Cancer
- Aug 21, 2023: Scale Biosciences And Basepair To Democratize Single Cell Sequencing Data Analysis
- Aug 16, 2023: 4BASES Announces the Readiness of a CFTR Mutations Detection Solution
- Aug 14, 2023: U.S. Food and Drug Administration (FDA) Approves FoundationOne CDx as a Companion Diagnostic for Janssen's AKEEGA (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
- Aug 02, 2023: Karius Test, a Liquid Biopsy for Infectious Diseases, Incorporated into Diagnostics Recommendation in the 2023 Duke-ISCVID Criteria for Infective Endocarditis
- Jul 27, 2023: NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
- Jul 24, 2023: Myriad Genetics Announces Inclusion of Breast Density to MyRisk with RiskScore Breast Cancer Risk Assessment
- Jul 12, 2023: Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study
- Jun 30, 2023: Novigenix Reports Interim European Validation Data on Its New NGS-Based Whole Blood RNA Signature for Detection of Advanced Colorectal Adenomas
- Jun 15, 2023: Neogenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
- Jun 12, 2023: FDA approves FoundationOne Liquid CDx as companion diagnostic for Braftovi
- Jun 12, 2023: Castle Biosciences Presents New Data Demonstrating the Ability of Decisiondx-SCC to Identify Tumors Likely to Metastasize in Patients With Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging
- Jun 08, 2023: Burning Rock's Precision Oncology Diagnostics Product Supports Advancement in Late- Stage Breast Cancer Treatment, With Results Published in the New England Journal of Medicine
- Jun 08, 2023: Imbdx Expands Targeted Therapies Agreement Following Successful Evaluation of Blood-Based Genomic Profiling Assay in Prostate Cancer
- Jun 08, 2023: Published in the New England Journal of Medicine
- Jun 05, 2023: Framework incorporating DecisionDx-SCC test results into clinical decision-making for patients with high-risk cutaneous squamous cell carcinoma published in Clinical, Cosmetic and Investigational Dermatology
- Jun 05, 2023: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
- Jun 02, 2023: Adaptive Biotechnologies highlights new data at ASCO 2023 and EHA 2023 underscoring the clonoSEQ assay's Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
- Jun 01, 2023: Labcorp introduces new liquid biopsy test
- May 31, 2023: Agendia studies reveal the influence of race on a tumor's biology, reinforcing its commitment to advancing research of racial disparities in breast cancer
- May 30, 2023: NeoGenomics to showcase the transformational impact of RaDaR assay for molecular residual disease and recurrence monitoring at ASCO
- May 25, 2023: Digi7 launches Geneyx AI-based solution to analyse next-generation sequencing data at Mediclinic
- May 23, 2023: Tempus Labs receives CLIA approval for xT CDx Test
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.